IOTA Pharmaceuticals Ltd

IOTA is a new-style pharmaceutical discovery company. Built around the scientific expertise and industrial experience of its founders, and leveraged by networked resources, IOTA possesses a wealth of discovery knowledge and experience which we place at your disposal.

Modern drug discovery has benefitted enormously from advances in human genomics. IOTA uses transcriptomics to provide individually-tailored gene family-based drug discovery platforms to address the involvement of specific members of gene families in human disease.

Our current therapeutic focus is glioblastoma. Glioblastoma is a brain cancer that typically attacks adults at the peak of their working lives and family responsibilities. Other cancers have been ameliorated or cured by modern medicine, but no currently available treatment, either chemical or surgical, appreciably slows the progression of glioblastoma, which is invariably fatal.

There is an urgent need for fresh approaches to this intractable cancer. Glioblastoma tumours are unresponsive to our current generalised weaponry of chemotherapy. IOTA has the ability to turn this promise into clinical efficacy in a reasonable timescale by using the tools we already have to hand in transformative ways.

IOTA has developed a suite of transcriptomics-based diagnostics that compare and contrast drug-treated, patient-derived tumour cells, looking in detail at the drug targets that they express, and defining specific FDA-approved drugs that could be used immediately in treatment strategies in the clinic.